Skip to main content

Table 2 Different outcomes assessed for the statistical analysis

From: Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients

Outcomes

Conditions

Data availability

Adverse 1

Treatment with bDMARD within 2 years

118/118

Adverse 2

HAQ > 1 or DAS28 > 5.1 while on csDMARDs

or treatment with bDMARD at 2 years

94/118

Favorable

DAS28 < 3.2 and HAQ ≤ 0.25 and no treatment

with bDMARD at 2 years

93/118